FDA 483 - Unknown Company - April 06, 2011

This FDA Form 483 document outlines three observations made during an inspection of a manufacturing facility.

**Observation 1:** The firm failed to establish an adequate quality control unit. This indicates a deficiency in the foundational structure responsible for ensuring product quality and compliance with regulations. An adequate quality control unit is crucial for overseeing all aspects of manufacturing that impact quality, including material control, production processes, and finished product release.

**Observation 2:** The firm did not adequately validate the cleaning procedures for manufacturing equipment. This means that the processes used to clean equipment, which are critical for preventing cross-contamination and ensuring product purity, have not been scientifically proven to be effective and consistent. Inadequate cleaning validation can lead to residues from previous batches or cleaning agents contaminating subsequent products.

**Observation 3:** The firm did not maintain proper records of batch production and control. This observation highlights a significant issue with documentation practices. Proper records are essential for demonstrating that each batch of product was manufactured according to established procedures, for traceability, and for investigating any quality issues that may arise. This includes records related to raw materials, in-process controls, and finished product testing.

Collectively, these observations point to systemic weaknesses in the facility's quality system and manufacturing controls, potentially impacting product quality, safety, and regulatory compliance. The lack of an adequate quality control unit appears to be an overarching issue contributing to the other deficiencies.